

Robert W Frenck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3514101/publications.pdf>

Version: 2024-02-01

50
papers

19,534
citations

257357

24
h-index

243529

44
g-index

53
all docs

53
docs citations

53
times ranked

27192
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
2	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
3	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
4	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
5	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
6	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	13.9	431
7	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	13.9	346
8	Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses. <i>American Journal of Gastroenterology</i> , 2006, 101, 1834-1840.	0.2	304
9	Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2015, 211, 870-878.	1.9	223
10	Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 148-154.	0.2	171
11	Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. <i>Vaccine</i> , 2014, 32, 2364-2374.	1.7	136
12	Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. <i>Vaccine</i> , 2013, 31, 3594-3602.	1.7	132
13	Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans. <i>Journal of Infectious Diseases</i> , 2012, 206, 1386-1393.	1.9	124
14	Serological Correlates of Protection against a GII.4 Norovirus. <i>Vaccine Journal</i> , 2015, 22, 923-929.	3.2	109
15	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. <i>Clinical Infectious Diseases</i> , 2021, 73, 336-340.	2.9	70
16	Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. <i>Vaccine Journal</i> , 2012, 19, 1296-1303.	3.2	64
17	Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. <i>Vaccine</i> , 2011, 29, 5666-5674.	1.7	63
18	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. <i>Clinical Infectious Diseases</i> , 2022, 75, 390-398.	2.9	60

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of a vaccine for extra-intestinal pathogenic <i>Escherichia coli</i> (ESTELLA): a phase 2 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 631-640.	4.6	53
20	Safety, tolerability, and immunogenicity of a 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. <i>Vaccine</i> , 2017, 35, 375-384.	1.7	52
21	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen <i>Staphylococcus aureus</i> vaccine in healthy older adults: Results of a randomised trial. <i>Vaccine</i> , 2017, 35, 385-394.	1.7	43
22	Efficacy, safety, and immunogenicity of the <i>Shigella sonnei</i> 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. <i>EClinicalMedicine</i> , 2021, 39, 101076.	3.2	37
23	Development of Pathogenicity-Driven Definitions of Outcomes for a Field Trial of a Killed Oral Vaccine against Enterotoxigenic <i>Escherichia coli</i> in Egypt: Application of an Evidence-Based Method. <i>Journal of Infectious Diseases</i> , 2004, 189, 2299-2307.	1.9	32
24	Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1086-1091.	1.1	32
25	A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against <i>Shigella sonnei</i> . <i>Vaccine</i> , 2018, 36, 4880-4889.	1.7	30
26	13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Not to 7-valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 183-189.	1.1	25
27	Immune Response Characterization after Controlled Infection with Lyophilized <i>Shigella sonnei</i> 53G. <i>MSphere</i> , 2020, 5, .	1.3	25
28	Consensus Report on <i>Shigella</i> Controlled Human Infection Model: Conduct of Studies. <i>Clinical Infectious Diseases</i> , 2019, 69, S580-S590.	2.9	24
29	Consensus Report on <i>Shigella</i> Controlled Human Infection Model: Clinical Endpoints. <i>Clinical Infectious Diseases</i> , 2019, 69, S591-S595.	2.9	23
30	Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. <i>Vaccine</i> , 2016, 34, 3454-3462.	1.7	22
31	The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 63-77.	1.4	20
32	Developing and utilizing controlled human models of infection. <i>Vaccine</i> , 2017, 35, 6813-6818.	1.7	20
33	Immunogenicity, Safety and Tolerability of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations in the United States. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 871-880.	1.1	19
34	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of <i>Shigella sonnei</i> 53G. <i>MSphere</i> , 2020, 5, .	1.3	13
35	<i>Shigella</i> -Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either <i>Shigella flexneri</i> 2a or <i>Shigella sonnei</i> . <i>MSphere</i> , 2021, 6, e0012221.	1.3	12
36	Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz532.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Melody Valve <i>Bartonella henselae</i> Endocarditis in an Afebrile Teen: A Case Report. <i>Pediatrics</i> , 2016, 137, .	1.0	9
38	Pharmacokinetics and pharmacogenomics of Î²-lactam-induced neutropenia. <i>Pharmacogenomics</i> , 2016, 17, 547-559.	0.6	7
39	Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. <i>Arthritis Care and Research</i> , 2010, 62, 903-906.	1.5	4
40	Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live <i>Shigella sonnei</i> vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. <i>PLoS ONE</i> , 2021, 16, e0259361.	1.1	4
41	Lot-to-lot consistency, safety and immunogenicity of 3 lots of <i>Haemophilus influenzae</i> type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. <i>Vaccine</i> , 2017, 35, 3564-3574.	1.7	2
42	Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e234-e235.	1.1	2
43	A cross-sectional household cluster serosurvey of hepatitis C virus antibodies in an urban slum of Cairo, Egypt in 2004. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2015, 1, 9.	0.9	1
44	<i>Shigella</i> -Controlled Human Infection Models: Current and Future Perspectives. <i>Current Topics in Microbiology and Immunology</i> , 2021, , .	0.7	1
45	599Rapid rises in antibody titers observed following single dose administration of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) to healthy adults. <i>Open Forum Infectious Diseases</i> , 2014, 1, S25-S25.	0.4	0
46	1098The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions. <i>Open Forum Infectious Diseases</i> , 2014, 1, S324-S324.	0.4	0
47	1102Immunogenicity and Safety of a Second Administration of 13-Valent Pneumococcal Conjugate Vaccine Five Years after Initial Vaccination in Adults 50 Years and Older. <i>Open Forum Infectious Diseases</i> , 2014, 1, S325-S326.	0.4	0
48	The Dynamics of <i>Staphylococcus aureus</i> carriage and Comparisons by Age in Two Studies of an Investigational <i>S aureus</i> 4-Antigen Vaccine (SA4Ag). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
49	Response to Letter to the Editor regarding: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18â€“49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2016, 34, 4467.	1.7	0
50	A site assessment tool for inpatient controlled human infection models for enteric disease pathogens. <i>Clinical Trials</i> , 2022, 19, 116-118.	0.7	0